New Ban in South Korea: 2 Ingredients Painful with Capillusine and Hat Pillarine Banned, Restrictions on Import of Foreign Food!
On August 23, 2024, the Korean Ministry of Food and Drug Safety issued an announcement No. 2024-392. The announcement updates the Guidelines for Designating and Lifting the Ban on the Import of Raw Material Ingredients of Domestic and Overseas Food Products, and adds katong and hyphenine as raw material ingredients of overseas food products that are prohibited to be imported into Korea.
Katong, derived from the leaves of "Mitragyna speciosa," a plant endemic to Southeast Asia, is rich in a variety of bioactive compounds, including components such as capillarine, which have opioid-like effects on the human body. When ingested in moderation, catarrhal pain may trigger stimulatory effects similar to caffeine; On the other hand, when ingested in excess, it may induce a sedative effect similar to that of opioids. Due to the potential health risks and addictions associated with the abuse of ketamine, it has been classified as a controlled substance in some countries, and its use in the medical and recreational fields is controversial. As a key bioactive ingredient in the leaves of kantong, capilline also has opioid effects, which may produce analgesic and sedative effects. At present, the mechanism of action and its potential medical value are still under in-depth study. Similar to catarrh, the overuse or abuse of capilline may also pose a health risk.
See the table below for details.
|
Index |
Ingredient Name |
Specified Date |
|
1 |
Kratom |
2024.08.23 |
|
2 |
Mitragynine |
2024.08.23 |
2026-08-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
From Painting Walls to Total Collapse: The RMB 152 Million Debt That Tore Off the Last Veil of Asia Chuangneng’s Paint Empire
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
Lilly’s Mounjaro Enters China’s State Insurance System
-
Vertex Pushes Gene Therapy Into Younger Children With Blood Disorders
-
Selling the Family Silver for a New Suit? Why Bohai Chemical’s Transformation Drama Got Canceled After Just Two Acts
-
Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
-
Arkema and ENNEX Forge Global Alliance to Power the Next Generation of Safer, Smarter Battery Separators
-
Sherwin-Williams Opens High-Performance Industrial Coatings Facility in Saskatchewan
Recommend Reading
-
“Milk Sugar 2.0” Cleared for Takeoff: EU Greenlights Next-Gen Human-Identical Oligosaccharide for Infant Nutrition
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Egypt’s Chemical Surge: $9.4 Billion Export Boom Signals Industrial Powerhouse Rise
-
U.S.-Iran Détente Triggers Oil Price Plunge, Energy and Chemical Sectors Tumble
-
DKSH to Distribute Point Grey’s Baby and Personal Care Portfolio in Vietnam
-
MTBE Market Trends: First Rise, Then Fall
-
Ethanol Market Prices at High Levels with Consolidation
-
BDO market trend continues to rise in China
-
This Week's Styrene Market Fluctuates and Declines (3.30-4.3)
-
Surge by 4,000 CNY/ton! Is the melamine market in China showing signs of peaking?